Disopyramide
From Wikipedia, the free encyclopedia
|
Disopyramide
|
|
| Systematic (IUPAC) name | |
| 4-dipropan-2-ylamino-2-phenyl-2-pyridin-2-yl-butanamide | |
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C21H29N3O |
| Mol. mass | 339.475 g/mol |
| Pharmacokinetic data | |
| Bioavailability | High |
| Protein binding | 50% to 65% (concentration-dependent) |
| Metabolism | Hepatic (CYP3A4-mediated) |
| Half life | 6.7 hours (range 4 to 10 hours) |
| Excretion | Renal (80%) |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral, intravenous |
Disopyramide (INN, trade names Norpace and Rythmodan) is an antiarrhythmic medication. It is a Class Ia antiarrhythmic used in the treatment of ventricular tachycardias. It has no effect on alpha or beta adrenergic receptors. It resembles Quinidine but it has a marked anti-muscarinic effect on the heart, for this reason, it is not considered as a drug of 1st choice. It is also used in ventricular arrhythmia and supraventricular arrhythmia that might follow myocardial infarctions.
[edit] Cardiac Adverse Effects
- Acute heart failure[1]
- Severe hypotension
[edit] Extracardiac Effects
- Dry mouth
- Constipation
- Urinary retention
- Blurred vision
- Glaucoma
- Rash
- Agranulocytosis
[edit] External links
|
|||||||||||||||||||||||||

